Fenwick represented Stoke Therapeutics, Inc. (NASDAQ: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, in its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105 million, after deducting underwriting discounts and commissions and estimated offering expenses.
J.P. Morgan Securities, Cowen and Company and Credit Suisse Securities (USA) acted as joint book-running managers in the offering. Canaccord Genuity and Cantor Fitzgerald & Co. acted as passive bookrunners in the offering.
More information can be obtained from Stoke’s announcement.
The Fenwick transaction team included corporate partner Robert Freedman, partner elect Julia Forbess and associates Michael Shaw and Joshua Fuller.